Clinical Trial Planning

Resource-Constrained Project Scheduling

A pharmaceutical company must schedule a Phase III clinical trial — protocol development, ethics review, patient screening, treatment phases, biomarker analysis — subject to precedence constraints and limited clinical staff, lab capacity, and data management resources. Each day of delay costs $1–2M in lost patent-protected revenue, making optimal scheduling critical to the drug development timeline.

Healthcare Decision Chain

Where clinical trial scheduling fits in the healthcare optimization hierarchy

Phase 1 Strategic Planning Clinical Trial Planning

Phase 2 Staff Planning Nurse Rostering

Phase 3 Patient Flow Bed Management

Phase 4 Supply Chain Drug Distribution

The Problem

Scheduling clinical trial activities under real-world constraints

Consider a Phase III cardiovascular drug trial. Each activity — writing the protocol, obtaining ethics approval, screening patients, conducting treatment phases, running biomarker analyses — has a duration (in weeks) and requires specific resources (clinical staff teams, laboratory units, data management units). Activities must obey precedence constraints: you cannot screen patients before ethics approval, and statistical analysis cannot begin until biomarker data is collected.

Resources are renewable: 4 clinical staff teams are available each week, 3 lab capacity units operate simultaneously, and 2 data management units process information in parallel. Activities that do not share a precedence relationship can run concurrently — but only if the combined resource demand does not exceed capacity. The objective is to minimize the trial duration (makespan), completing all activities as early as possible to reach market before patent expiration.

Clinical Trial Domain	OR / RCPSP Concept
Trial activities (Protocol, Screening, Treatment, ...)	Activities with durations d_i
Must-finish-before relationships	Precedence constraints (i, j) ∈ E
Clinical Staff (4 teams)	Renewable resource R₁ = 4
Lab Capacity (3 units)	Renewable resource R₂ = 3
Data Management (2 units)	Renewable resource R₃ = 2
Total trial duration	Makespan C_max = S_n+1
Minimize time-to-market	minimize C_max

RCPSP Formulation (PS | prec | C_max) minimize S_n+1 // start time of sink = trial duration
subject to
  S_j ≥ S_i + d_i // precedence: j cannot start before i finishes
  Σ_{i active at t} r_ik ≤ R_k ∀ t, k // resource capacity per period
  S_i ≥ 0 // non-negative start times

The RCPSP is strongly NP-hard, even with just two resource types. For clinical trials with 12+ activities and 3 resource types, the number of feasible schedules grows combinatorially. Real trials rely on heuristic Schedule Generation Schemes (SGS) and metaheuristics like Genetic Algorithms to find near-optimal schedules. RCPSP scheduling can reduce trial duration by 10–20%, saving tens of millions in time-to-market costs.

Scheduling Theory & RCPSP Family

Try It Yourself

Edit activities, precedences, and resource capacities, then schedule the clinical trial

Clinical Trial Scheduler

12 Activities · Staff 4 · Lab 3 · Data 2

Scenario

Resource Capacities

Staff: 4

Lab: 3

Data Mgmt: 2

Activities

#	Activity Name	Duration (wk)	Staff	Lab	Data	Predecessors

Algorithms

Serial SGS — LFT (H) Parallel SGS (H) Genetic Algorithm (M)

Gantt Chart

Resource Usage Profile

Results Comparison

Algorithm	Makespan (weeks)	Resource Delay	Avg Utilization	Time (ms)

Select a scenario and click "Solve & Compare All Algorithms" to see results.

Business Impact Translation

Cost per week of delay:

Trials per year:

Complete a solve to see business impact analysis.

The Algorithms

Schedule Generation Schemes and metaheuristics for clinical trial scheduling

Key Insight

The RCPSP heuristics build feasible schedules by iteratively selecting an unscheduled activity and assigning it a start time respecting both precedence and resource constraints. The Genetic Algorithm wraps a Serial SGS as a decoder, evolving permutations of activities to explore the solution space more broadly than a single priority rule.

Serial SGS — LFT

Heuristic · Active Schedules

Activities are prioritized by Latest Finish Time (ascending): activities that must finish earliest get scheduled first. The LFT is computed via a backward pass from the sink node. This ensures critical-path activities are given priority access to resources.

Compute LFT via backward pass from the trial completion milestone
Sort eligible activities by LFT ascending
For each activity: find earliest time t where all predecessors are finished AND staff, lab, data capacity allows it
Schedule the activity at time t, update resource profiles

Parallel SGS

Heuristic · Non-Delay Schedules

Instead of iterating over activities, the Parallel SGS iterates over time points. At each decision point, it schedules as many eligible activities as resources allow, then advances time to the next activity completion event. This avoids unnecessary resource idle time.

Start at t = 0. Identify all activities with completed predecessors
Among eligible, schedule those whose resource demand fits (by LFT priority)
Advance t to the next activity completion time
Repeat until all trial activities are scheduled

Genetic Algorithm

Metaheuristic · Population-Based

A population of activity permutations is evolved over 100 generations. Each permutation is decoded into a feasible schedule using Serial SGS. Crossover recombines successful orderings; mutation shuffles activity positions. The GA explores more of the solution space than a single priority rule.

Initialize population of 30 random activity permutations
Decode each permutation via Serial SGS, evaluate makespan fitness
Tournament selection, order crossover (OX), swap mutation
Repeat for 100 generations, return best schedule found

Real-World Complexity

Why clinical trial scheduling is harder than the textbook model

Real-World Complications

Regulatory dependencies — FDA/EMA interactions, IRB reviews, and Data Safety Monitoring Board (DSMB) meetings create external milestones the scheduler cannot control
Multi-resource contention — Clinical research associates, laboratory equipment, biostatisticians, and CRO partners all compete across multiple concurrent trials
Duration variability — Patient recruitment rates are stochastic; enrollment can take 2x longer than planned, especially for rare diseases or competitive indications
Critical path risk — Adverse events, protocol amendments, or manufacturing failures can halt the trial, requiring re-scheduling of downstream activities
Multi-site coordination — Global trials span 50+ sites across time zones, each with its own regulatory and operational constraints

Key References

Foundational papers on clinical trial scheduling and pharmaceutical R&D optimization

DiMasi, J.A., Grabowski, H.G. & Hansen, R.W. (2016). "Innovation in the pharmaceutical industry: New estimates of R&D costs." Journal of Health Economics, 47, 20–33. DOI: 10.1016/j.jhealeco.2016.01.012
Petrovic, D., Tanev, D. & Gorgievski, A. (2012). "Resource-constrained project scheduling for clinical trials." International Journal of Project Management, 30(4), 449–462.
Colvin, M. & Maravelias, C.T. (2008). "A stochastic programming approach for clinical trial planning." Computers & Chemical Engineering, 32(11), 2626–2642. DOI: 10.1016/j.compchemeng.2007.11.010

Need to optimize clinical trial scheduling?

From Phase I dose escalation to Phase III pivotal trials, resource-constrained scheduling drives drug development efficiency. Let's discuss how mathematical optimization can accelerate your pipeline.

Connect on LinkedIn

Disclaimer

Data shown is illustrative. Activity durations, resource requirements, and trial structure are simplified for educational purposes and do not represent any specific clinical trial or pharmaceutical company's development program.